Drug War Daily Digest – November 9, 2026

A California investigation exposes gaps in cannabis pesticide screening, Compass completes its psilocybin application, and the Philippine Truth Commission seeks scrutiny of drug-war death certificates.

Marijuana Policy

California Investigation Finds Gaps in Cannabis Pesticide Screening. California's cannabis-testing system is missing hazardous chemicals outside its required screening list, Paige St. John reports in a November 8 Los Angeles Times investigation. Testing commissioned by the newspaper found improvements in some previously contaminated brands, but also chemicals regulators do not routinely test for. The reporting describes lengthy enforcement delays and incentives to substitute pesticides that escape required screens. The Department of Cannabis Control defended its testing, surveillance and enforcement system. The newspaper's methods account, by St. John and Sean Greene, says three laboratories screened 49 inhalable products for a combined 376 pesticides. Some purchases targeted brands with earlier contamination problems, and the sample included exceptions to California-licensed products. The results therefore do not establish contamination rates across the market. Some comparisons also use future California limits or federal tobacco-testing benchmarks rather than current cannabis limits.

Hemp

Illinois Enforcement Pause. CBS Chicago reports Illinois paused enforcement against hemp plaintiffs and association members through November 19; broader relief remains pending.

Texas Hemp Appeal Arguments Canceled Ahead of Change in Court. The 15th Court of Appeals has canceled December 8 arguments in a challenge to Texas hemp rules, leaving the matter for the three newly elected Democratic justices who take office in January, Zach Leggio reports in The Texas Tribune. The outgoing court also canceled arguments in three other cases so it could finish opinions in cases already heard. The challenged rules include testing, packaging and recordkeeping requirements and steep license-fee increases: manufacturers' fees rose from $258 to $10,000 per facility and retail registration from $155 to $5,000. A Travis County judge temporarily blocked the rules in April. The scheduling change does not decide their legality.

Medical Marijuana

Lawyers Warn DEA Registration Policy Threatens Dual-Purpose Cannabis Licenses. A new analysis by Dickinson Wright attorneys Christopher Lynch and Benjamin M. Sobczak examines how federal medical marijuana registration could exclude businesses serving both medical and adult-use customers. They describe an October 27 DEA order proposing to deny a Minnesota dispensary's application on three grounds: its dual-purpose state license, dispensing without a practitioner's certification, and state permission to sell artificially derived cannabinoids. The order remains contestable, not a final denial. The authors warn that similar licensing structures and affiliated adult-use businesses elsewhere could face scrutiny. Their November 9 analysis also identifies uncertainties in DEA's nonbinding supply-chain guidance, including the treatment of existing inventory and relationships with applicants that missed the filing window. They caution that the guidance does not override state restrictions on interstate cannabis transfers.

Florida Proposes Delivery-Device and Harvest-Failure Rules. Florida's November 6 Administrative Register contains proposed nonemergency rules governing medical marijuana delivery devices and transfers after crop losses. The device proposal addresses department approval, restrictions on child-appealing designs, dispensing consistent with a patient's approved route of administration, and recalls. The harvest-failure proposal would allow approved transfers after qualifying losses of at least half a harvest, with documentation, testing and tracking requirements. Transfers could not exceed the amount lost, and a business would need department approval before acquiring replacement cannabis. These are proposals replacing emergency-rule provisions, not newly adopted rules; comments may be submitted through November 27.

German Providers Challenge Proposed Telemedicine and Mail-Order Restrictions. German cannabis providers and pharmacists challenged the case for tighter medical access at last week's Cannabis Health Symposium, Ben Stevens reports in Business of Cannabis. The proposed changes would require an in-person consultation for an initial prescription and prohibit mail-order cannabis dispensing, but have not been enacted. Speakers acknowledged problems including weak identity checks, aggressive marketing and questionable prescribing at some platforms, while arguing that targeted standards would be preferable to restrictions affecting all patients. They proposed certification requirements covering identity and age verification, consultations, documentation and prescriber qualifications. Pharmacy representatives also raised concerns about platform fees, proliferating products and pressure on pharmacists to investigate how prescriptions were obtained. The report presents industry arguments and data, rather than an independent finding that all telemedicine practices are safe.

Psychedelics

Compass Completes Psilocybin Application to FDA. Compass Pathways announced November 9 that it has completed its new drug application for COMP360, its investigational synthetic psilocybin formulation for treatment-resistant depression. This is the completed submission previously expected within two weeks, not FDA approval. The company says its application draws on two Phase 3 trials and a Phase 2b study involving more than 1,000 participants. It is preparing for a possible launch in the first half of 2027, contingent on approval and the federal and state scheduling changes needed to market the treatment. Psychedelic Alpha reports that the filing joins pending applications involving Usona's psilocybin treatment and Resilient Pharmaceuticals' MDMA treatment.

Drug Policy

Pennsylvania Overdose Prosecution Review Highlights Uneven Use and Rescue Concerns. Pennsylvania recorded 684 criminal cases carrying a drug-delivery-resulting-in-death charge from 2021 through 2025, Ed Mahon reports in a new Spotlight PA review. Lancaster, Monroe, Cumberland and York counties accounted for a disproportionate share relative to their populations. The charge can bring up to 40 years in prison, and critics say it can target people sharing drugs and discourage calls for emergency assistance; some bereaved families instead see prosecution as necessary accountability. Pennsylvania was not among the six states offering an affirmative defense for good-faith efforts to obtain emergency help in a national 2024 legal analysis cited by the report. A separate media-based database ranked Pennsylvania first for such cases during 2011–2022, but does not capture every prosecution. The article's 21,392 overdose deaths for 2021–2025 are a different measure from criminal cases, and its 2025 death data are preliminary.

Extrajudicial Killings

Oversight Report Describes Boat-Strike Pause, Targeting Review and Resumption. The lead inspector general's October 29 report on Operation Southern Spear describes a pause in maritime strikes beginning in late June for Venezuela earthquake assistance and a review of targeting procedures, followed by resumed strikes in August. Covering July through September, it attributes four lethal strikes and 13 people killed or presumed dead to Southern Command, and says revised guidance sought better identification of targeted vessels. It also describes two ongoing oversight evaluations: one concerning intelligence processing and dissemination, the other compliance with the military's targeting process. Those evaluations are not completed findings clearing the strikes. The report says most agency information it compiles was not independently audited or verified. Its account is a retrospective quarterly record, not a report of new November attacks.

Philippine Truth Commission Requests Investigation of Death Certificates. The Philippine Truth Commission formally asked the Professional Regulation Commission on November 9 to examine death certificates for 13 drug-war victims and determine whether the signing doctors should face disciplinary proceedings. Its letter asks the Board of Medicine to identify the physicians, examine the basis for the recorded causes of death, preserve records and investigate whether similar practices occurred in other cases. The commission says discrepancies identified through its work have deprived families of accurate official accounts. It offered the certificates to the regulator and said corrections would also require cooperation from civil registrars, health authorities and the Philippine Statistics Authority. The request does not establish that the regulator has opened proceedings or found misconduct.

Families and Pathologist Challenge Accounts of Two 2017 Killings. At the Philippine Truth Commission's November 6 session, relatives of Christopher Lazaro and Alberto Paragas described pressure to accept police accounts of the men's deaths in Marilao, Bulacan, in August 2017. Marissa Lazaro said officers demanded money and delayed providing records; Rizza Quiamco said police sought her signature on a document supporting their version. Forensic pathologist Raquel Fortun reported inconsistencies among death certificates, a medico-legal report and her examination of exhumed remains. She said a report describing Lazaro's stomach contents could not be reconciled with a body whose organs had not been examined, and raised questions about documented wrist-binding marks. These are attributed testimony and forensic assessments presented at the session, which our earlier coverage previewed; they are not new killings or a judicial determination of officers' liability.

Duterte Defense Challenges Expert Evidence Ahead of Trial. Rodrigo Duterte's lawyers have asked the International Criminal Court to exclude a prosecution expert's report and supporting material, arguing that prosecutors submitted them after the evidence-list deadline without first obtaining permission. Janna Millenas reports in VERA Files that the defense also objects to two studies it says the expert did not substantively use and other documents it calls redundant. The defense argues that the volume and timing would disrupt trial preparation. Trial Chamber III had not ruled on the application or objections in the November 9 report. Prosecutors separately submitted an updated witness list identifying expected remote testimony and the proposed order of appearances. The drug-war crimes-against-humanity trial is scheduled to begin November 30.

Philippine Police Report Hundreds of Leads in Dela Rosa Search. Police chief Jose Melencio Nartatez Jr. said officers had checked roughly 500 leads concerning Senator Ronald "Bato" Dela Rosa's whereabouts, including remote islands, Karen De Guzman reports for ABS-CBN News. Authorities are seeking to execute the ICC arrest warrant, and the government has offered a P50-million reward. Nartatez also said police were examining reports of possible interference and warned of administrative or criminal consequences where evidence warranted them. His November 9 statement describes the search effort; it does not establish an arrest or a confirmed location.

International System

UN Experts Question Mexico on Methadone and Harm Reduction Access. During the review of Mexico that concluded November 6, members of the UN Committee on Economic, Social and Cultural Rights asked about access to methadone, harm reduction programs and residential support for people who use drugs. The UN meeting summary records the delegation describing a human-rights-based addiction policy, training for teachers and frontline workers, and more than 1.6 million prevention activities during 2024–2026. Those responses describe government initiatives but do not establish that the access questions were resolved. The committee was still preparing its concluding observations; the hearing summary is not a final finding or an adopted policy change.

Harm Reduction

Tusi Reporting Highlights Unpredictable Drug Mixtures. A November 9 analysis by Abby Pender in InSight Crime describes a drug market in which the name "tusi" identifies a variable mixture rather than a consistent substance. Although its name derives from 2C-B and it is often marketed as "pink cocaine," the reporting says ketamine commonly forms the base, with ingredients varying by producer and local supply. It cites Colombian drug-checking group Echele Cabeza's finding of up to 18 compounds across samples, not necessarily within one sample. Mixing and coloring existing drugs requires less infrastructure than synthesizing them, making production difficult to attribute to a single organization. The analysis underscores why a product's color or street name cannot establish its contents or effects.

Research

Overdose Trends and Emerging Benzodiazepines

A county-level analysis by Kale Williams and Brad Jennings in Axios finds overdose deaths fell in all 14 Oregon counties with sufficient data to determine a trend. Provisional CDC counts for the 12 months ending March 2026 show Multnomah County declining from 494 to 315 deaths, Clackamas from 105 to 60, and Washington from 99 to 52. Small counts are suppressed in other counties, preventing some comparisons. These are rolling-year figures, not totals for calendar 2026, and the analysis does not establish that a particular policy caused the declines.

UNODC's November 6 review of emerging benzodiazepines reports 51 distinct substances during the preliminary 2025–2026 reporting period, including 17 newly reported by multiple countries across four continents. It distinguishes geographical spread from the frequency of detections in drug samples and cautions that reporting varies among countries. The agency describes declining bromazolam detections following international scheduling alongside increased reports of alternatives, while etizolam continues to appear years after scheduling. It calls for updated laboratory methods and rapid information sharing to identify new compounds and metabolites. The publication supplies surveillance evidence; it does not announce a new scheduling decision.

Events

The Forum on the Arms Trade and Center for International Policy will hold their annual conference in Washington, DC, December 2, from 9:00am to 11:30am Eastern. A 9:30am panel on Latin America and boat strikes lists Adam Isacson of WOLA, Daniel Noroña of Amnesty International USA and Annie Shiel of the Center for Civilians in Conflict. Attendance is free; the downtown venue remains to be confirmed.

The North Carolina Harm Reduction Coalition's 20th-anniversary gathering is scheduled for December 1–2 at the Koury Convention Center in Greensboro. The event page provides registration and reduced-rate information; the hotel booking deadline is November 10.

The Beyond the Laboratory webinar on academic cannabis research is scheduled for November 18 at 2:00pm Eastern, with Linda Klumpers and Riana Durrett.